- Conditions
- Coronary Artery Disease
- Interventions
- PB127 for injectable suspension
- Drug
- Lead sponsor
- Point Biomedical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 428 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • San Francisco, California • Stanford, California + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 5,123
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- Safinamide (as add-on therapy)
- Drug
- Lead sponsor
- Newron Pharmaceuticals SPA
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 679 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Oxnard, California + 27 more
- Conditions
- Bacterial Vaginosis
- Interventions
- Metronidazole
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 15 Years to 25 Years · Female only
- Enrollment
- 1,370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 3 more
- Conditions
- Focal Epilepsy
- Interventions
- Not listed
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 488 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • San Francisco, California • Denver, Colorado + 19 more
- Conditions
- Aortic Stenosis, Severe
- Interventions
- SAPIEN X4 THV, SAPIEN X4S
- Device
- Lead sponsor
- Edwards Lifesciences
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2037
- U.S. locations
- 58
- States / cities
- La Jolla, California • Los Angeles, California • Newport Beach, California + 44 more
- Conditions
- Ovarian Neoplasms
- Interventions
- intravenous T900607-sodium
- Drug
- Lead sponsor
- Tularik
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 5
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 2 more
- Conditions
- Postoperative Cognitive Dysfunction
- Interventions
- Florbetapir F 18 (18F-AV-45), no intervention
- Drug · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Medication Adherence, HIV Prevention, Stimulant Use
- Interventions
- PARTI, Attention-Control, Contingency Management for PrEP Adherence
- Behavioral
- Lead sponsor
- Florida International University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 239 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- San Francisco, California • Miami, Florida
- Conditions
- HIV Infections
- Interventions
- Early Treatment with HAART, No treatment, HAART Treatment - standard care
- Drug · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 24 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 20
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more
- Conditions
- Prostate Cancer
- Interventions
- bicalutamide, flutamide, LHRH agonist (antagonist) therapy, Dose-Escalated Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,538 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2025
- U.S. locations
- 499
- States / cities
- Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 353 more
- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide, Bortezomib, Dexamethasone, Autologous Stem Cell Transplant
- Drug · Procedure
- Lead sponsor
- Paul Richardson, MD
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 729 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Duarte, California + 37 more
- Conditions
- VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery
- Interventions
- JNJ-64179375 0.3 mg/kg, JNJ-64179375 0.6 mg/kg, JNJ-64179375 1.2 mg/kg, JNJ-64179375 (Dose to be Determined), JNJ-64179375 A mg/kg, JNJ-64179375 B mg/kg, JNJ-64179375 C mg/kg, JNJ-64179375 D mg/kg, Placebo JNJ-64179375, Apixaban placebo, Apixaban 2.5 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 308 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Torrance, California • Englewood, Colorado + 4 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- XL184
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 8
- States / cities
- Los Angeles, California • San Francisco, California • Boston, Massachusetts + 5 more
- Conditions
- Adenovirus, Primary Immune Deficiency Disorder
- Interventions
- cytotoxic t-lymphocytes
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 1 Month to 79 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 6 more
- Conditions
- Long COVID, Post-Acute Sequela of COVID-19, Post-Acute COVID-19
- Interventions
- AER002, Placebo
- Drug · Other
- Lead sponsor
- Michael Peluso, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Breast Neoplasms
- Interventions
- Iza-bren, Nab-paclitaxel, Paclitaxel, Capecitabine, Carboplatin, Gemcitabine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 46
- States / cities
- Hot Springs, Arkansas • Cerritos, California • Long Beach, California + 35 more
- Conditions
- Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Cyclophosphamide, Fludarabine Phosphate, Ibrutinib, Laboratory Biomarker Analysis, Pharmacogenomic Study, Quality-of-Life Assessment, Rituximab
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 529 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 781
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 509 more
- Conditions
- Kidney Disease, Chronic
- Interventions
- BI 764198, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 20
- States / cities
- Huntsville, Alabama • San Francisco, California • South Gate, California + 17 more
- Conditions
- Ventricular Premature Beats, Contractions, or Systoles, Cardiomyopathies
- Interventions
- Radiofrequency ablation, Amiodarone (Antiarrhythmic drug)
- Procedure · Drug
- Lead sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Not listed
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 29 more
- Conditions
- HIV Infection
- Interventions
- Not listed
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 12 Years to 24 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 11 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 12 Years to 35 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 23
- States / cities
- Orange, California • Palo Alto, California • San Francisco, California + 20 more
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- Interventions
- 89Zr-DFO-YS5, YS5 antibody, Positron Emission Tomography (PET)/Computerized tomography (CT), Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)
- Drug · Biological · Procedure
- Lead sponsor
- Robert Flavell, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Onychomycosis
- Interventions
- IDP-108, Vehicle
- Drug
- Lead sponsor
- Dow Pharmaceutical Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 870 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 29 more